Anti-ErbB3 antibodies and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 28, 2020
Grant Date -
Feb 8, 2018
app pub date -
Oct 25, 2017
filing date -
Sep 30, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2017 Application Filing Year
- A61K Class
- 21227 Applications Filed
- 12841 Patents Issued To-Date
- 60.50 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 1 Citation Count
- A61K Class
- 66.68 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Oct 28, 2027 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Oct 28, 2031 |
